Quanterix Co. (NASDAQ:QTRX) Shares Purchased by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System lifted its position in Quanterix Co. (NASDAQ:QTRXGet Rating) by 82.8% during the second quarter, HoldingsChannel.com reports. The fund owned 23,401 shares of the company’s stock after acquiring an additional 10,600 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Quanterix were worth $379,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Royce & Associates LP boosted its stake in shares of Quanterix by 8.3% in the second quarter. Royce & Associates LP now owns 250,748 shares of the company’s stock worth $4,060,000 after acquiring an additional 19,200 shares during the last quarter. Candriam S.C.A. boosted its stake in Quanterix by 20.0% during the second quarter. Candriam S.C.A. now owns 90,000 shares of the company’s stock worth $1,457,000 after buying an additional 15,000 shares during the last quarter. SG Americas Securities LLC acquired a new position in Quanterix during the second quarter worth $181,000. Versor Investments LP acquired a new position in Quanterix during the second quarter worth $624,000. Finally, Assenagon Asset Management S.A. boosted its stake in Quanterix by 302.8% during the second quarter. Assenagon Asset Management S.A. now owns 163,800 shares of the company’s stock worth $2,652,000 after buying an additional 123,139 shares during the last quarter. 91.85% of the stock is owned by institutional investors and hedge funds.

Quanterix Stock Up 4.9 %

NASDAQ:QTRX opened at $11.73 on Monday. Quanterix Co. has a 52 week low of $6.31 and a 52 week high of $47.26. The company has a market capitalization of $434.66 million, a P/E ratio of -4.41 and a beta of 1.32. The stock’s fifty day moving average is $10.11 and its two-hundred day moving average is $13.47.

Analyst Ratings Changes

A number of research firms have weighed in on QTRX. Canaccord Genuity Group lowered Quanterix from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $40.00 to $12.00 in a research note on Monday, August 15th. Cowen lowered Quanterix from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $38.00 to $18.00 in a research note on Tuesday, August 9th. Cowen lowered Quanterix from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 9th. Canaccord Genuity Group lowered Quanterix from a “buy” rating to a “hold” rating in a research note on Tuesday, August 16th. Finally, The Goldman Sachs Group reduced their target price on Quanterix from $15.00 to $13.00 and set a “neutral” rating on the stock in a research report on Thursday, November 10th. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $26.00.

Quanterix Company Profile

(Get Rating)

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.

Featured Articles

Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Co. (NASDAQ:QTRXGet Rating).

Institutional Ownership by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.